Table 3. Treatment sequence from first physician‐assessed tumor progression and analysis of time to next progression (n = 185).
a
Patients with two or more therapies excluding octreotide are counted as receiving combination therapy.
b
Other therapies include aflibercept (Eylea), pemetrexed (Alimta), axitinib (Inlyta), denosumab (Xgeva, Prolia), endostatin, ganitumab/AMG‐479, pembrolizumab (Keytruda), telotristat ethyl/ telotristat etiprate (Xermelo), VB‐111, and zoledronic acid (Zometa).
Abbreviations: CC, cytotoxic chemotherapy; EBRT, external beam radiation therapy; LDT, liver‐directed therapy; NA, not available; PRRT, peptide receptor radiotherapy; TT, targeted therapy.